(Reuters) – The European Union’s drugs regulator on Thursday recommended conditionally approving Johnson & Johnson (NYSE:)’s single dose COVID-19 vaccine, as the bloc seeks to speed up a stuttering inoculation campaign and boost its supplies of vaccines.
The COVID-19 shot is the fourth to be endorsed for use in the EU after vaccines from Pfizer-BioNTech, AstraZeneca-Oxford University and Moderna (NASDAQ:), and is recommended for those over 18 years of age, the European Medicines agency (EMA) said.
The United States, Canada and Bahrain have also approved the shot. South Africa is carrying out an expedited review.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.